Stockscreener 앱 받기
2.30
7.98%
0.17
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO Pharma reports successful FDA meeting on urcosimod clinical trial - Investing.com
OKYO Pharma reports positive FDA feedback on planned neuropathic corneal pain trial - Proactive financial news
OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment - Investing.com
OKYO Pharma Wins FDA Backing on Phase 2b/3 Design for Urcosimod in Neuropathic Corneal Pain - TipRanks
FDA backs 120-patient eye pain trial for OKYO's urcosimod - Stock Titan
OKYO Pharma stock gets FDA compassionate use approval for urcosimod By Investing.com - Investing.com Nigeria
OKYO Pharma stock gets FDA compassionate use approval for urcosimod - Investing.com
FDA Approves Single-Patient Compassionate Use of Urcosimod for the Treatment of Neuropathic Corneal Pain - VisionMonday
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain - Sahm
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain By Investing.com - Investing.com India
Small cap wrap: Medicus Pharma, OKYO, American Resources... - Proactive financial news
FDA authorizes expanded access use of OKYO Pharma’s urcosimod for single patient By Investing.com - Investing.com South Africa
OKYO Pharma gets FDA nod for compassionate use of eye drug in neuropathic corneal pain - Proactive Investors
FDA authorizes expanded access use of OKYO Pharma’s urcosimod for single patient - Investing.com
Okyo announces FDA authorized single-patient expanded IND for urcosimod - TipRanks
OKYO Pharma Wins FDA Compassionate-Use Clearance for Urcosimod in Severe Neuropathic Corneal Pain - TipRanks
FDA authorizes compassionate use of urcosimod for neuropathic corneal pain - Investing.com
FDA authorizes compassionate use for OKYO’s nerve pain med - grafa.com
Aug Summary: Is OKYO Pharma Limited a turnaround storyQuarterly Growth Report & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Portfolio Shifts: Can OKYO Pharma Limited beat the S P 500Trade Volume Report & Technical Pattern Alert System - baoquankhu1.vn
Market Trends: Can OKYO Pharma Limited beat the S P 500Gap Down & Smart Investment Allocation Insights - baoquankhu1.vn
Leadership watch: OKYO, Orbis, and BVI Medical name new CEOs - Eyes On Eyecare
Will OKYO Pharma Limited stock recover faster than marketJuly 2025 Opening Moves & Daily Volume Surge Signals - bollywoodhelpline.com
Published on: 2026-01-18 23:27:28 - baoquankhu1.vn
Can Whitehawk Therapeutics Inc sustain its profitability2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Update - MarketBeat
OKYO Pharma (NASDAQ:OKYO) Trading Down 15.5%What's Next? - MarketBeat
Published on: 2026-01-13 10:43:18 - baoquankhu1.vn
Aug Technicals: Can OKYO Pharma Limited maintain sales growth2025 Stock Rankings & Verified Momentum Stock Ideas - baoquankhu1.vn
Risk Hedge: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Return Stock Opportunities - moha.gov.vn
Is OKYO Pharma Limited stock affected by interest rate hikes2025 Growth vs Value & Weekly High Conviction Ideas - ulpravda.ru
Dividend Watch: Will OKYO Pharma Limited stock benefit from green energy trendsMarket Volume Report & Daily Profit Maximizing Tips - Улправда
Can OKYO Pharma Limited stock resist market sell offsSell Signal & Technical Confirmation Alerts - ulpravda.ru
Will OKYO Pharma Limited stock benefit from green energy trendsQuarterly Earnings Summary & Weekly Hot Stock Watchlists - Улправда
Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 Patterns & Real-Time Buy Signal Alerts - Улправда
Will OKYO Pharma Limited stock outperform growth indexesStop Loss & Detailed Earnings Play Strategies - Улправда
Will OKYO Pharma Limited stock benefit from automationEarnings Recap Summary & Weekly Setup with ROI Potential - Улправда
Entry Recap: Can OKYO Pharma Limited stock beat analyst upgradesJuly 2025 PostEarnings & Fast Gain Swing Trade Alerts - Улправда
What Wall Street predicts for OKYO Pharma Limited stock priceQuarterly Trade Review & Weekly Top Stock Performers List - Улправда
Is OKYO Pharma Limited stock trading at a premium valuationTechnical Pattern Recognition & Identify Winning Stocks - ulpravda.ru
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target - Investing.com Nigeria
OKYO Pharma appoints Robert Dempsey as new CEO By Investing.com - Investing.com Nigeria
OKYO Pharma Limited's (NASDAQ:OKYO) Intrinsic Value Is Potentially 90% Above Its Share Price - Yahoo Finance
OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential - TipRanks
OKYO Pharma appoints Ophthalmology veteran Robert Dempsey as new CEO - Proactive financial news
OKYO Pharma names ophthalmology veteran Robert Dempsey as CEO - Proactive financial news
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer - BioSpace
OKYO Pharma names Robert J. Dempsey as chief executive officer By Investing.com - Investing.com India
OKYO Pharma names Robert J. Dempsey as chief executive officer - Investing.com
OKYO Pharma Names Ophthalmology Veteran Robert J. Dempsey as CEO to Drive Next Growth Phase - TipRanks
OKYO Pharma appoints Robert Dempsey as new CEO - Investing.com
1.17%
3.10%
자본화:
|
볼륨(24시간):